BioSpace News Archive

ACGME President and Chief Executive Officer Thomas J. Nasca, MD, MACP announced yesterday that he intends to step down from his current role on January 1, 2025, to establish the ACGME Center for Professionalism and the Future of Medicine.

RaySearch Laboratories AB announces that the Froedtert & Medical College of Wisconsin health network, USA, has placed an order for the treatment planning system RayStation®*.

Applied Science announced the launch of its latest whole blood collection automation solutions - the HemoFlow 500 Series of blood mixer and scale devices and HemoVue, a cloud-based service that integrates with both the HemoFlow 500 and existing HemoFlow 400 devices to provide real-time operational data and analytics that significantly improve blood collection and related processes.

Celularity Inc. (Nasdaq: CELU) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder.

Sheppard Pratt is pleased to announce that Matthew W. Johnson , PhD, will join the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt as a senior researcher for its Center of Excellence for Psilocybin Research and Treatment in February 2024.

NBME renews the Latin America Grants Program to continue its commitment to advancing innovative approaches to medical education and enriching the evaluation of health professionals.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that RareCyte Inc., a precision biology company based in Seattle, Washington, is live on SOPHiA GENETICS.

Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from the lead-in portion of the Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-targeting antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (uHCC).

Verastem Oncology (Nasdaq:VSTM) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Verastem Oncology’s investigational RAF/MEK clamp, avutometinib, in combination with Amgen’s KRAS G12C inhibitor, LUMAKRASTM (sotorasib), for the treatment of patients with KRAS G12C-mutant metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy and have not been previously treated with a KRAS G12C inhibitor.

Nevro Corp. announced that Carelon Healthcare, a healthcare services company dedicated to delivering whole-person care with connected healthcare solutions for better outcomes and experiences, will be publishing a new interventional pain management policy that expands spinal cord stimulation coverage for painful diabetic neuropathy.